Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

A Multicomponent Approach to Screening for Dementia in Older Hospitalized Patients

Tan ZS, Qureshi N, Sicotte NL, Hirsch D, Escovedo C, Spivack E, Nasmyth MC, Gonzales M, Kremen SA, Nuckols TK, Mafi J, McFadden J, Roberts[...]

Disparities in Healthcare Seeking and Physician Diagnosis of Irritable Bowel Syndrome: Results from a US Survey

Almario CV, Liu J, Higgins C, Yerneni N, Boules M, Chey WD, Chang L. Disparities in Healthcare Seeking and Physician Diagnosis of Irritable Bowel Syndrome:[...]

Correlates and prognostic value of left atrial strain in transcatheter edge-to-edge repair for degenerative mitral regurgitation

Shechter A, Taheri H, Kaewkes D, Nagasaka T, Suruga K, Gupta A, Patel V, Koren O, Koseki K, Skaf S, Makar M, Patel D, Chakravarty[...]